FDA Approves First RSV Vaccine for Infants Through Maternal Immunization Program

• The Centers for Medicare & Medicaid Services (CMS) proposed making Medicare drug price negotiations permanent starting June 12, 2026, to lower prescription costs for Americans. • Separate health data from FAIR Health for Q1 2026 reveals that mental health is the leading telehealth diagnosis across all U.S. age groups and regions, affecting 52.1% of patients.

• Biotech companies including Soligenix, Moderna, Regeneron, and Aethlon Medical are accelerating the development of vaccines and therapeutics to combat a global outbreak of Bundibugyo ebolavirus in 2026. • Regeneron's maftivimab, a potent antibody found in the FDA-approved Inmazeb, has been recommended by the WHO's Therapeutics Advisory Group for use in clinical trials.

• On June 2, 2026, the FDA approved ensitrelvir for the post-exposure prophylaxis of COVID-19 in patients aged 12 years and older. • The regulatory decision follows positive results from phase 3 clinical trials, confirming the drug's efficacy in this demographic.

• CMS has released new physician guidance regarding the Medicare GLP-1 Bridge Program, creating a potential pathway for weight management medication coverage. • This program bypasses the long-standing federal law that has excluded Medicare Part D coverage for drugs used solely for weight loss.

• The CDC is currently responding to Ebola disease outbreaks occurring in the Democratic Republic of the Congo (DRC) and Uganda. • The agency has issued specific health guidance and monitoring information for travelers returning to the United States from the DRC, Uganda, and South Sudan.

• A CIDRAP op-ed argues that the United States has officially lost its status as a measles-eliminated country, asserting that current outbreaks represent continuous internal spread rather than isolated reintroductions. • The author criticizes the use of cautious phrasing by health officials, noting that the evidence from the virus itself confirms a failure to maintain elimination.

• The June 26, 2026, Health Equity & Access roundup highlights critical gaps in obesity coding and rising rates of Mantle Cell Lymphoma (MCL) among women. • Dr. Bhavana “Tina” Bhatnagar of the West Virginia University Cancer Institute notes that Acute Myeloid Leukemia (AML) is now viewed as a collection of molecularly distinct diagnoses.

• Two new reports, including one from the CDC's Morbidity and Mortality Weekly Report, analyze the difficulties in containing recent measles outbreaks within the U.S. • The studies focus on a major outbreak that began on October 2, 2025, in Spartanburg County, South Carolina, marking the largest U.S. outbreak since the disease was declared eliminated in 2000.

• JAMA Network Open has published a taxpayer-funded study on COVID-19 vaccines that federal officials at the CDC previously declined to release. • The study examines vaccine efficacy and safety, raising questions about why the CDC initially squelched the data and whether the decision was based on political motivations or a desire to protect public confidence.

• WHO Director-General Tedros Adhanom Ghebreyesus announced that clinical trials for two experimental drugs will launch next week in the Democratic Republic of the Congo. • The trials will evaluate whether the antivirals MBP134 and remdesivir, provided via donations from the United States and Gilead Sciences, can reduce mortality rates.

• Allies of HHS Secretary Robert F. Kennedy Jr. are working to embed his vaccine agenda within institutions by influencing research priorities and policy translation, despite ongoing legal and political challenges. • New York health officials have accused Tiger Medical Holdings of "smuggling" alloClae, a popular injectable filler derived from human fat, into the state.

• HHS Secretary Robert F. Kennedy Jr. stated on Monday that the United States must reclaim its position as the global leader in medical research and innovation. • Kennedy highlighted a competitive gap, noting that China is currently conducting more early-stage clinical trials than the U.S.